Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Equity Ratio (2019 - 2025)

Vivos Therapeutics has reported Equity Ratio over the past 7 years, most recently at 0.06 for Q4 2025.

  • Quarterly Equity Ratio fell 111.38% to 0.06 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.06 through Dec 2025, down 111.38% year-over-year, with the annual reading at 0.06 for FY2025, 111.38% down from the prior year.
  • Equity Ratio was 0.06 for Q4 2025 at Vivos Therapeutics, down from 0.1 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.79 in Q3 2021 and troughed at 0.06 in Q4 2025.
  • The 5-year median for Equity Ratio is 0.4 (2023), against an average of 0.39.
  • Year-over-year, Equity Ratio skyrocketed 11101.71% in 2024 and then crashed 111.38% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.76 in 2021, then crashed by 53.84% to 0.35 in 2022, then crashed by 89.05% to 0.04 in 2023, then surged by 1258.65% to 0.52 in 2024, then crashed by 111.38% to 0.06 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Equity Ratio are 0.06 (Q4 2025), 0.1 (Q3 2025), and 0.18 (Q2 2025).